

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



HUTCHMED (China) Limited

和黃醫藥（中國）有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 13)

OVERSEAS REGULATORY ANNOUNCEMENT

This announcement is issued pursuant to Rule 13.10B of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited.

Please refer to the attached announcement which has been published by HUTCHMED (China) Limited on the website of the U.K. Regulatory Information Service on March 13, 2025.

By Order of the Board

Edith Shih

Non-executive Director and Company Secretary

Hong Kong, March 13, 2025

As at the date of this announcement, the Directors of the Company are:

Chairman and Non-executive Director:

Dr Dan ELDAR

Executive Directors:

Dr Weiguo SU

*(Chief Executive Officer and
Chief Scientific Officer)*

Mr CHENG Chig Fung, Johnny

(Chief Financial Officer)

Non-executive Directors:

Ms Edith SHIH

Ms Ling YANG

Independent Non-executive Directors:

Mr Paul Rutherford CARTER

(Senior Independent Director)

Dr Renu BHATIA

Dr Chaohong HU

Mr Graeme Allan JACK

Professor MOK Shu Kam, Tony

Mr WONG Tak Wai



Notice of Extraordinary General Meeting

Hong Kong, Shanghai, & Florham Park, NJ — Thursday, March 13, 2025: HUTCHMED (China) Limited (“[HUTCHMED](#)” or the “Company”) (Nasdaq/AIM: HCM; HKEX: 13) today announces that its Circular (including Notice of Extraordinary General Meeting) and the Form of Proxy (“EGM Materials”), will be posted on March 14, 2025 to those shareholders who have elected to receive the EGM Materials in printed form. The documents can also be accessed from the HUTCHMED website (www.hutch-med.com).

The 2025 Extraordinary General Meeting (“EGM”) will be an electronic/hybrid meeting to be held at 47th Floor, Cheung Kong Center, 2 Queen’s Road Central, Hong Kong on Monday, March 31, 2025 at 3:00 pm Hong Kong Time (8:00 am London Time), with online access through an online platform as detailed in the EGM Materials.

The EGM is being convened for the purposes of approving the Company’s proposed disposal of its 45% equity interest in Shanghai Hutchison Pharmaceuticals Limited (as first announced January 1, 2025 and further announced on March 2, 2025). Shareholders are encouraged to read the EGM Materials in full.

About HUTCHMED

HUTCHMED (Nasdaq/AIM:HCM; HKEX:13) is an innovative, commercial-stage, biopharmaceutical company. It is committed to the discovery, global development and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. Since inception, HUTCHMED has focused on bringing drug candidates from in-house discovery to patients around the world, with its first three medicines marketed in China, the first of which is also approved in the US, Europe and Japan. For more information, please visit: www.hutch-med.com or follow us on [LinkedIn](#).

CONTACTS

Investor Enquiries

+852 2121 8200 / ir@hutch-med.com

Media Enquiries

FTI Consulting –

+44 20 3727 1030 / HUTCHMED@fticonsulting.com

Ben Atwell / Alex Shaw

+44 7771 913 902 (Mobile) / +44 7779 545 055 (Mobile)

Brunswick – Zhou Yi

+852 9783 6894 (Mobile) / HUTCHMED@brunswickgroup.com

Panmure Liberum

Nominated Advisor and Joint Broker

Atholl Tweedie / Freddy Crossley / Rupert Dearden

+44 20 7886 2500

HSBC

Joint Broker

Simon Alexander / Alina Vaskina / Arnav Kapoor

+44 20 7991 8888

Cavendish

Joint Broker

Geoff Nash / Nigel Birks

+44 20 7220 0500